-transparent.png){kind=logo}
The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s significantly changed the therapeutic approach for rheumatoid arthritis (RA). With the approval of subsequent TNF inhibitors as well as other biologic agents effective in the management of RA, the treatment paradigm has become increasingly complex. This review examines the current literature regarding the efficacy and toxicity of these and other new anti-rheumatic therapies and discusses effective therapeutic strategies for their use.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Michael G Feely
May 2004,
Rheumatic diseases clinics of North America,
Michael G Feely
June 2013,
Expert opinion on emerging drugs,
Michael G Feely
April 2006,
Biotechnology healthcare,
Michael G Feely
December 2007,
Lancet (London, England),
Michael G Feely
July 2005,
Journal of clinical pharmacology,
Michael G Feely
June 2001,
The American journal of managed care,
Michael G Feely
January 2006,
Journal of infusion nursing : the official publication of the Infusion Nurses Society,
Michael G Feely
January 1995,
The British journal of clinical practice,
